Please use this identifier to cite or link to this item:
Title: HERC2 deficiency activates C-RAF/MKK3/p38 signalling pathway altering the cellular response to oxidative stress
Author: Sala-Gaston, Joan
Pedrazza, Leonardo
Ramirez, Juanma
Martinez-Martinez, Arturo
Rawlins, Lettie E.
Baple, Emma L.
Crosby, Andrew H.
Mayor, Ugo
Ventura, Francesc
Rosa López, José Luis
Keywords: Ubiqüitina
Issue Date: 14-Oct-2022
Publisher: Springer Science and Business Media LLC
Abstract: HERC2 gene encodes an E3 ubiquitin ligase involved in several cellular processes by regulating the ubiquitylation of different protein substrates. Biallelic pathogenic sequence variants in the HERC2 gene are associated with HERC2 Angelman-like syndrome. In pathogenic HERC2 variants, complete absence or marked reduction in HERC2 protein levels are observed. The most common pathological variant, c.1781C > T (p.Pro594Leu), encodes an unstable HERC2 protein. A better understanding of how pathologic HERC2 variants affect intracellular signalling may aid definition of potential new therapies for these disorders. For this purpose, we studied patient-derived cells with the HERC2 Pro594Leu variant. We observed alteration of mitogen-activated protein kinase signalling pathways, reflected by increased levels of C-RAF protein and p38 phosphorylation. HERC2 knockdown experiments reproduced the same effects in other human and mouse cells. Moreover, we demonstrated that HERC2 and RAF proteins form molecular complexes, pull-down and proteomic experiments showed that HERC2 regulates C-RAF ubiquitylation and we found out that the p38 activation due to HERC2 depletion occurs in a RAF/MKK3-dependent manner. The displayed cellular response was that patient-derived and other human cells with HERC2 deficiency showed higher resistance to oxidative stress with an increase in the master regulator of the antioxidant response NRF2 and its target genes. This resistance was independent of p53 and abolished by RAF or p38 inhibitors. Altogether, these findings identify the activation of C-RAF/MKK3/p38 signalling pathway in HERC2 Angelman-like syndrome and highlight the inhibition of RAF activity as a potential therapeutic option for individuals affected with these rare diseases.
Note: Reproducció del document publicat a:
It is part of: Cellular and Molecular Life Sciences, 2022, vol. 79, issue. 11
Related resource:
ISSN: 1420-9071
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
s00018-022-04586-7.pdf7.74 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons